ID93+GLA-SE (QTP101)
Candidate Overview
ID93+GLA-SE / QTP101 consists of the active pharmaceutical ingredient, a recombinant protein ID93, and an adjuvant, GLA-SE. The ID93 recombinant protein is composed of the four Mtb antigens Rv3619, Rv1813, Rv3620, and Rv2608 linked in tandem. GLA is a molecule similar to synthetic monophosphoryl lipid A (MPL®) as a TLR4 agonist.
Sponsor / Lead Developer: Quratis (QTP101); NIAID/NIH (ID93+GLA-SE)
Clinical Trial Status: No Active Trials
Primary Indication: Prevention of TB disease
Other Indication(s): Prevention of Mtb infection or sustained infection and Prevention of TB recurrence
Target Population(s): Adolescents and Adults
Clinical Trials
COMPLETED TRIALS |
|
| Registry Number | NCT03806686 |
| Clinical Trial Phase | Phase 2a |
| Clinical Trial Sponsor | Quratis Inc. |
| Primary endpoint(s) for this clinical trial | Safety |
| Target population(s) for clinical trial | Adults |
| People without Mtb infection | |
_________________________ |
|
| Registry Number | NCT03806699 |
| Clinical Trial Phase | Phase 1 |
| Clinical Trial Sponsor | Quratis Inc. |
| Primary endpoint(s) for this clinical trial | Safety |
| Target population(s) for clinical trial | Adolescents |
| People without Mtb infection | |
_________________________ |
|
| Registry Number | NCT02508376 |
| Clinical Trial Phase | Phase 1 |
| Clinical Trial Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Primary endpoint(s) for this clinical trial | Safety |
| Target population(s) for clinical trial | Adults |
_________________________ |
|
| Registry Number | NCT02465216 |
| Clinical Trial Phase | Phase 2a |
| Clinical Trial Sponsor | Access to Advanced Health Institute (AAHI) (formerly IDRI) |
| Primary endpoint(s) for this clinical trial | Safety |
| Target population(s) for clinical trial | Adults |
| People cured of TB | |
_________________________ |
|
| Registry Number | NCT03722472 |
| Clinical Trial Phase | Phase 1 |
| Clinical Trial Sponsor | AAHI |
| Primary endpoint(s) for this clinical trial | Safety |
| Target population(s) for clinical trial | Adults |
_________________________ |
|
| Registry Number | NCT02465216 |
| Clinical Trial Phase | Phase 2a |
| Clinical Trial Sponsor | AAHI |
| Primary endpoint(s) for this clinical trial | Safety |
| Target population(s) for clinical trial | Adults |
| People cured of TB disease | |
_________________________ |
|
| Registry Number | NCT01927159 |
| Clinical Trial Phase | Phase 1 |
| Sponsor | AAHI |
| Primary endpoint(s) for this clinical trial | Safety |
| Target population(s) for clinical trial | Adults |
_________________________ |
|
| Registry Number | NCT01599897 |
| Clinical Trial Phase | Phase 1 |
| Clinical Trial Sponsor | AAHI |
| Primary endpoint(s) for this clinical trial | Safety |
| Target population(s) for clinical trial | Adults |
Related Publications
- Safety and immunogenicity of the ID93 + GLA-SE tuberculosis vaccine in BCG-vaccinated healthy adjults: A randomized, double-blind, placebo-controlled Phase 2 trial. (Infect Dis Ther, 2023)
- Safety and immunogenicity of a thermostable ID93 + GLA-SE tuberculosis vaccine candidate in healthy adults (Nt. Commun., 2023)
- Safety and immunogenicity of the adjunct therapeutic vaccine ID93 + GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trial (Lancet Respir. Med., 2020)
- The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial (NPJ Vaccines, 2018)
- Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial (Lancet Respir. Med., 2018)
- The Importance of Adjuvant Formulation in the Development of a Tuberculosis Vaccine (J Innumol, 2012)
- A Defined Tuberculosis Vaccine Candidate Boosts BCG and Protects Against Multidrug-Resistant Mycobacterium tuberculosis (Sci Transl Med., 2010)
Additional Information
Quratis is planning for a phase 2b/3 dose exploration and efficacy, safety, and immunogenicity trial of QTP101.
NIAID/NIH is planning a Phase 2a/2b safety and immunogenicity study of ID93+GLA-SE given as a therapeutic adjunct.